Prescription patterns and drug costs in German patients with dementia in nursing homes and home-care settings [0.03%]
德国养老院和家庭护理环境中痴呆症患者的处方模式和药物费用
Louis Jacob,Jens Bohlken,Karel Kostev
Louis Jacob
Aims: To analyze prescription patterns and drug costs in German patients with dementia who are in home-care settings and nursing homes. Methods: ...
Pharmacokinetic comparison of two formulations of talniflumate 370 mg tablets in healthy Korean volunteers [0.03%]
370毫克塔利氟马特片两种剂型在健康韩国受试者中的药代动力学比较研究
Yun Kim,Sung- Yim,Bo-Hyung Kim et al.
Yun Kim et al.
Background: Talniflumate, a prodrug of niflumic acid, is a potent analgesic and anti-inflammatory drug that has been widely used for the treatment of rheumatoid diseases. ...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2017 Jan;55(1):102-108. DOI:10.5414/CP202707 2017
N-terminal probrain natriuretic peptide in patients with acute coronary syndrome [0.03%]
急性冠脉综合征患者的脑钠肽氨基末端前体激素检测价值分析
Qi Kang,Zheng Wan,Zhenwen Huang
Qi Kang
Objective: To observe the changes and evaluate the significance of serum N-terminal probrain natriuretic peptide (NT-proBNP) levels in patients with acute coronary syndrome and to discuss its clinical significance and rel...
Replacement of SFC-DPI with SFC-MDI exhaled through the nose improves eosinophilic chronic rhinosinusitis in patients with bronchial asthma [0.03%]
鼻呼气SFC-MDI替代SFC-DPI可改善伴支气管哮喘的嗜酸性慢性鼻窦炎患者的症状
Yoshiki Kobayashi,Mikiya Asako,Takahisa Yamamoto et al.
Yoshiki Kobayashi et al.
Objective: Eosinophilic chronic rhinosinusitis (ECRS), a subgroup of chronic rhinosinusitis with nasal polyps, is a refractory disease closely associated with bronchial asthma. We recently reported on the efficacy of ultr...
Pharmacokinetics and safety of the selective progesterone receptor modulator vilaprisan in healthy postmenopausal women [0.03%]
选择性孕激素受体调节剂维拉利普森在健康绝经后妇女中的药代动力学和安全性
Marcus-Hillert Schultze-Mosgau,Barbara Schuett,Frank-Thorsten Hafner et al.
Marcus-Hillert Schultze-Mosgau et al.
Objectives: Vilaprisan is a novel, potent, and highly selective progesterone receptor modulator, which might offer a promising option for the treatment of uterine fibroids. ...
Utilization of population pharmacokinetics in drug development and provision of the results to healthcare professionals [0.03%]
人群药代动力学在药物研发及临床实践中的应用
Megumi Watanabe-Uchida,Mamoru Narukawa
Megumi Watanabe-Uchida
Objective: The aim of this research is to understand the level of utilization of population pharmacokinetics (PPK) in drug development in the United States of America (US) and Japan, and to discuss what kind of PPK inform...
Comparative pharmacokinetic and bioequivalence evaluation of two formulations of morniflumate 350-mg tablets in healthy male subjects [0.03%]
350毫克莫尼福玛特片两种剂型的药代动力学及生物等效性评价
Heechan Lee,Sung-Vin Yim,Bo-Hyung Kim et al.
Heechan Lee et al.
Background: Morniflumate is a nonsteroid anti-inflammatory drug (NSAID) that inhibits cyclooxygenase-1, 2 (COX-1, 2). Objective: This s...
Randomized Controlled Trial
International journal of clinical pharmacology and therapeutics. 2017 Jan;55(1):95-101. DOI:10.5414/CP202678 2017
Pharmacokinetics and safety of indacaterol and glycopyrronium (IND/GLY) following repeated once daily inhalation from a fixed-dose combination in healthy Chinese subjects [0.03%]
健康受试者中每日一次固定剂量联合制剂吸入茚达特罗/格隆溴铵的药代动力学和安全性研究
Shuang Ren,Romain Sechaud,Zhenzhong Su et al.
Shuang Ren et al.
Objective: Indacaterol/glycopyrronium (IND/GLY) is a once-daily fixed-dose combination of two long-acting bronchodilators: indacaterol 110 µg (long-acting β2-adrenergic agonist, LABA) and glycopyrronium 50 µg (long-act...
Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with severe renal impairment: A single-dose, open-label, parallel-group study [0.03%]
司柏西利马（BAF312）在重度肾损害患者中的药代动力学、安全性和耐受性：一项单剂量、开放标签、平行组研究
Anne Gardin,Angela Dodman,Sampath Kalluri et al.
Anne Gardin et al.
Objective: To investigate the pharmacokinetics (PK), safety, and tolerability of siponimod and selected inactive metabolites (M3 and M5) in subjects with varying degrees of renal impairment (RI) compared to demographicall...
CYP3A4*1G and CYP3A5*3 genetic polymorphisms alter the antihypertensive efficacy of amlodipine in patients with hypertension following renal transplantation [0.03%]
CYP3A4*1G和CYP3A5*3基因多态性改变肾移植后高血压患者氨氯地平的降压疗效
Yun Huang,Gaiyan Wen,Yao Lu et al.
Yun Huang et al.
Objective: Previous studies have determined that CYP3A and multidrug resistance protein 1 (MDR1) polymorphisms can affect the pharmacokinetics and pharmacodynamics of amlodipine in both healthy subjects and those with ear...